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Objective: Pulmonary inflammatory pseudotumor is an uncommon disease, often with a benign presentation.
However, invasion of adjacent thoracic organs, local recurrence, and distant metastases have been described,
and the best management strategy remains unclear. We present a single large institutional experience in patients
with pulmonary inflammatory pseudotumor and propose guidelines for treatment of this patient population.
Methods: A retrospective study was performed to review all patients who underwent resection for pulmonary
inflammatory pseudotumor between 1974 and 2007.
Results:A total of 25 patients were treated with pulmonary inflammatory pseudotumor at the Marie Lannelongue
Hospital. The mean age was 33 years. Two patients were referred after an incomplete resection. One patient pre-
sented with cerebral metastasis. We performed a complete resection in all patients: wedge resection (n ¼ 7), lo-
bectomy (n ¼ 6), sleeve arterial lobectomy (n ¼ 1), lobectomy with thoracic inlet exenteration (n ¼ 2),
bilobectomy (n¼ 2), pneumonectomy with brain metastasectomy (n¼ 1), sleeve pneumonectomy (n¼ 2), sleeve
main bronchus or tracheal resection (n ¼ 2), wedge with sleeve main pulmonary artery resections (n ¼ 1), and
sleeve pneumonectomy with esophageal, aortic arch, and right pulmonary artery resection (n ¼ 1). No adjuvant
therapy was given to any patients. Postoperative 30-day mortality and morbidity rates were 4% and 8%, respec-
tively. With a mean follow-up of 80 months (range 4–369 months, 100% follow-up), actuarial 10-year survival
was 89%. One patient died of an extensive sarcomatous recurrence 2 years after surgery.
Conclusion: Pulmonary inflammatory pseudotumor is a malignant disease affecting young patients with local
invasion, distant metastasis, local recurrence, and sarcomatous degeneration. A complete resection should always
be performed at initial presentation because of its high likelihood of cure with aggressive management.Inflammatory pseudotumor (IPT) of the lung is a rare and not
well-described disease. This disease has presented in the lar-
ynx, retroperitoneum, and abdomen. The lung is the most
common site of localization, accounting for 0.7% of all tho-
racic tumors.1-12 In children aged less than 16 years, IPT is
the most frequent primary pulmonary tumor.13 Although
IPT is usually considered to be a benign entity, local inva-
sion, local postoperative recurrence, and distant metastases
have been described. Its histologic presentation and natural
history are widely variable; therefore, a variety of terms
have been used to identify this disease, including plasma
cell granuloma,7 inflammatory myofibroblastic tumor,12
xanthogranuloma,14 or fibrous histiocytoma.5 Because of
this inconsistency in pathologic diagnosis and the small
number of patients typically seen with this disease, the treat-
ment of choice remains debated.
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doi:10.1016/j.jtcvs.2008.07.009The Journal of Thoracic and CAt the Marie Lannelongue Hospital, we have approached
this disease as a low-grade sarcoma. Therefore, it has been
our policy to perform a complete R0 resection whenever
possible. Patients with pulmonary IPT are typically young;
therefore, an aggressive approach is warranted to maximize
the likelihood of long-term cure. We retrospectively re-
viewed our single-center experience to determine the effec-
tiveness of complete resection of pulmonary IPT.
MATERIALS AND METHODS
We performed a chart review of all patients who presented to the Marie
Lannelongue Hospital between 1974 and 2007. We identified 26 patients
with pulmonary IPT. One patient was not deemed suitable for surgery be-
cause of a bulky tumor invading the esophagus, descending aorta, and left
atrium, which was associated with poor conditions that precluded extended
surgery. This patient was treated medically by imatinib and steroids. A le-
thal aortoesophageal fistula developed in the patient 6 months later, and
he was excluded from the present study. All the remaining 25 patients un-
derwent surgery in our department. This patient population accounted for
0.05% of all thoracic surgical procedures performed during this period. Re-
cords of the patients with pulmonary IPT were reviewed, and the following
data were collected: clinical presentation, medical history, laboratory data,
and radiologic findings at the time of diagnosis, diagnostic procedure, sur-
gical treatment, postoperative complications, and long-term follow-up. The
study was approved by our institutional review board.
The preoperative workup included physical examination, chest radiogra-
phy, computed tomography of the chest and upper abdomen, computed to-
mography or magnetic resonance imaging of the brain, bronchoscopy,
spirometry, arterial blood gas measurement, ventilation-perfusion scanning,
and electrocardiography. F-18 fluorodeoxyglucose positron emissionardiovascular Surgery c Volume 137, Number 2 435
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tomography was performed for only recent cases (n ¼ 2) and demonstrated
a lesion with intense F-18 fluorodeoxyglucose activity with a standardized
uptake value of 10 and 8, respectively. In patients at high risk, a right-sided
heart catheterization was performed before and after balloon occlusion of
the relevant pulmonary artery to detect pulmonary hypertension.
Tumor resection was considered complete when the resection margins
were free of disease. Two pathologists (V.M. and E.D.) independently re-
viewed the histologic specimens of all cases to confirm the diagnosis of
IPT. Immunophenotyping was determined by immunohistochemical stain-
ing on 5-mm–thick, formalin-fixed, paraffin-embedded tissue sections, and
clonality was characterized according to the type of immunoglobulin on ma-
lignant cell surface in all cases. Tissue sections were incubated with mono-
clonal antibodies 1) to cytokeratins (AE 1–3 clone; Dako, Carpinteria, Calif;
1:125) to rule out a spindle cell carcinoma, 2) to smooth muscle actin (1A4
clone; Dako; 1:100), 3) to anaplastic lymphoma kinase-1 (Dako; 1:100), and
4) to CD34 and S100 protein.
Tumors were classified according to the criteria defined by Gal and col-
leagues2 and the World Health Organization.15 The histologic type defined
byMatsubara and colleagues16 as organizing pneumonia was excluded from
this review because of its non-neoplastic nature. Follow-up data were
obtained by telephone or patient’s hospital visit.
Determination of long-term follow-up was calculated from the date of di-
agnosis to the date of death or the last follow-up visit. Continuous data are
presented as mean  standard error unless otherwise noted. Survivals were436 The Journal of Thoracic and Cardiovascular Surcalculated by life-table analysis with the date of resection of the IPT as the
starting time. Kaplan–Meier curves were plotted and compared using the
log-rank test for univariate analysis with StatView V (Abacus Concepts,
Berkeley, Calif).
RESULTS
There were 14 women and 11 men, with a median age of
33 years (range, 9–74 years). Fifteen patients (60%) were
aged less than 30 years. The tumor was located in the trachea
in 1 patient, the right lung in 14 patients (56%), and the left
lung in 10 patients (44%).
Clinical Characteristics
A history of cancer was found in 5 patients (20%), includ-
ing breast cancer (n ¼ 1), testis cancer (n ¼ 1), retroperito-
neal fibrosarcoma (n ¼ 1), bronchioloalveolar carcinoma
(n ¼ 1), and vocal cord carcinoma (n ¼ 1) (Table 1).
Thirteen patients (52%) were symptomatic and presented
with cough (n ¼ 5), fever (n ¼ 4), dyspnea (n ¼ 3), dyspha-
gia (n ¼ 1), or chest pain related to T1 nerve root invasion
(n ¼ 1). The remaining patients were asymptomatic, and
their lung tumors were discovered incidentally on routine
chest radiographs.
Two patients were referred after an incomplete resection
at a different institution. One of them (patient number 10),
an 11-year-old child, had undergone operation 3 timesTABLE 1. Characteristics of patients who underwent complete surgical resection of inflammatory pseudotumor
Patient No. Age, y Sex History of cancer Size (cm) Recurrence Site of primary lesion Cerebral metastasis Follow-up (mo)
1 26 M 3.5 No LLL No 369
2 26 F 3 No LLL No 26
3 13 M 4 No RUL, ML No 244
4 29 F 4 No RP, carina No 223
5 20 F 7 No RUL No 152
6 19 F 1 No Trachea No 123
7 18 M 2 No RUL No 113
8 48 F 2.5 No LUL, LPA No 96
9 26 F 3.2 No LLL No 104
10 11 M 13 No Extensive LP No 0
11 36 F Breast cancer 1.5 No LUL No 100
12 22 M Testicular cancer 1 No RUL No 97
13 39 M 1.5 No ML No 62
14 29 F 2.2 No RUL No 53
15 12 M Fibrosarcoma 1 Yes RUL No 27
16 54 F 5 No RUL, ML No 38
17 55 M Bronchoalveolar cancer 4 No Pancoast No 12
18 9 F 2 No RUL No 20
19 40 F 2.5 No RP, carina No 15
20 30 M 3.5 No LUL No 20
21 70 F 3 No RPA No 60
22 58 M 0.6 No LLL No 19
23 74 M Vocal cord cancer 5 No Pancoast No 25
24 19 F 11 No RP Yes 7
25 37 F 1.5 No LMB No 4
LLL, Left lower lobectomy; LUL, left upper lobectomy; ML, middle lobectomy; RP, right pneumonectomy; RUL, right upper lobectomy; RPA, right pulmonary artery; LPA, left
pulmonary artery; LMB, left main bronchus; extensive LP, left sleeve pneumonectomy with esophageal, aortic arch, and right pulmonary artery resection.gery c February 2009
Fabre et al General Thoracic SurgeryFIGURE 1. Angiography and chest computed tomography of patient 10 with an invasion of the left pulmonary artery, a tumoral stenosis of the right pul-
monary artery, and an involvement of the oesophagus who had undergone operation 3 times before with uncompleted resection for an invasive mediastinal
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mediastinal variant (Figure 1). The residual mass had been
managed with postoperative radiation therapy (45 Gy) and
steroid therapy. This treatment failed to control the tumor lo-
cally and resulted in recurrence with invasion of the left
atrium, pulmonary artery with a severe pulmonary hyperten-
sion, aortic arch, carina, and esophagus (Figure 1). He was
then referred to the Marie Lannelongue Hospital for a sal-
vage procedure.
The other patient (patient number 17) was referred for
a right lung tumor invading the right thoracic inlet (first
rib, subclavian artery and vein, and T1 nerve root) with chest
pain. After failure to obtain negative surgical margins, adju-
vant radiation therapy (50 Gy) was given at an outside insti-
tution. The patient was then referred 6 months later to our
department because of further growth of the residual tumor
mass.
Preoperative Workup
A pulmonary mass (>4 cm) was found in 7 patients and
calcified in 6 of them (Figure 2). On bronchoscopy, we
found an endobronchial lesion in 2 patients. Sixteen patients
presented with a solitary nodule or lobar infiltrate. One pa-
tient (number 24) was found with 2 brain metastases during
the preoperative workup.
Preoperative histologic diagnosis was obtained in 8 pa-
tients by surgical (n ¼ 2), bronchoscopic (n ¼ 4), or com-
puted tomography scan-guided (n ¼ 2) biopsy. In the
remaining 17 patients, a frozen section was performed dur-
ing surgery to obtain a diagnosis. In 12 of the 17 patients,
the pathologist could make a definitive diagnosis of pulmo-
nary IPT based on the frozen section. The remaining 5 pa-
tients were further reviewed before a final decision was
issued.
Surgical Resection
A complete resection was always performed. The extent
of resections included wedge resection (n ¼ 7), lobectomy
(n ¼ 6), sleeve arterial lobectomy (n ¼ 1), lobectomy ex-The Journal of Thoracic and Ctended to the thoracic inlet (n ¼ 2), bilobectomy (n ¼ 2),
pneumonectomy with brain metastasectomy (n ¼ 1), sleeve
pneumonectomy (n ¼ 2), sleeve main bronchus or tracheal
resection (n ¼ 2), sleeve left arterial pneumonectomy (n ¼
1), and sleeve pneumonectomy with esophageal, aortic
arch, and right pulmonary artery resection and replacement
(n ¼ 1). Resection was performed using a cardiopulmonary
bypass in 2 patients. For tumors invading the thoracic
inlet, an anterior approach as described by Dartevelle and
colleagues17 was performed in 1 patient and a posterior
approach as described by Shaw and colleagues18 was per-
formed in 1 patient.
Histologic Findings
The mean tumor diameter was 3.5 cm (range, 0.6–13 cm).
The histologic types were myofibroblastic inflammatory
tumor (n ¼ 16) when there was a spindle-cell component
expressing smooth muscle actin, fibrous histiocytic type
(n¼ 8) when the spindle cell did not express smooth muscle
actin, and unclassified (plasma cell granuloma, n ¼ 1).
Mycobacterial and fungal infections were ruled out in all
cases by culture.
Immunohistochemically, reactions of monoclonal anti-
bodies against cytokeratins (AE 1–3), CD34, S100 protein,
and anaplastic lymphoma kinase-1 were always negative.
However, tumor reactivity for smooth muscle actin (1A4
clone) was exhibited in 18 patients (72%).
Operative Mortality and Morbidity
Postoperative mortality and morbidity rates were 4% and
8%, respectively. The patient who underwent sleeve pneu-
monectomy with esophageal, aortic arch, and right pulmo-
nary artery resection and replacement died postoperatively
of multiorgan failure. Postoperative complications occurred
in 2 other patients, including a pneumonia that was managed
with intravenous antibiotics and an empyema without bron-
chopleural fistula that was managed by a chest tube. In all
patients, the median length of stay was 11 days (range, 7–
25 days). A blood cell transfusion was required in 2 patients.ardiovascular Surgery c Volume 137, Number 2 437
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lung. This patient also presented cerebral localization with the same histology of IPT.The patient was then referred 6 months later to our depart-
ment because of further growth of the residual tumor mass.
Survival
According to the policy for these lesions at the Marie Lan-
nelongue Hospital, no adjuvant treatment was given on dis-
covery. Patients were closely followed at 3-month intervals
for 1 year and then annually. Every visit included a physical
examination and a computed tomography scan. No patients
were lost to follow-up. During the study, 1 patient died of an
extensive sarcomatous recurrence 27 months after surgery.
The remaining 23 patients are currently alive without evi-
dence of recurrence. With a median follow-up of 80 months
(range, 4–369 months), overall 5- and 10-year disease-free
survivals were 89%, respectively (Figure 3). Univariate
analysis demonstrated that the only risk factor for poor
outcome was the need for reoperation for tumor recurrence
(5-year survival, 0% vs 96%, P ¼ .005). However, the
significance of this statistical test should be considered
with precaution because of the small number of patients.
The young patient (number 24) with cerebral metastasis is
currently alive without cerebral recurrence.
DISCUSSION
Thoracic IPTs typically present as small peripheral tu-
mors. They constitute 0.7% to 1% of all tumors of the
lung.15,16 The incidence of these tumors is 0.04%.4 At the
Marie Lannelongue Hospital they represented 25 of
44,019 thoracic procedures between 1974 and 2007, an inci-
dence of 0.05%. In our series, 15 patients (62%) were aged
less than 30 years. According to the reported literature, pul-
monary IPTs are the most frequently diagnosed pediatric
primary lung tumor.6,7,9,16,19-22 Both sexes are equally af-
fected. No geographic or ethnic predominance has been re-
ported. The precise cause of IPT of the lung is unknown.
IPT of the lung is thought to be an uncontrolled response
to tissue damage of chronic inflammation. The inciting in-
jury would seem to be related to a pulmonary infection.23
No genetic predisposition or environmental exposure has438 The Journal of Thoracic and Cardiovascular Surbeen linked to this disease. A history of a pulmonary infec-
tion has been reported. In our series, 5 patients (21%) had
a history of cancer. This trend has not been described in pre-
vious reports.
Fifty percent of patients were asymptomatic in our series,
which is comparable to other reports. The tumor is fre-
quently discovered on routine chest radiograph and presents
as a solitary calcified mass with no evidence of malig-
nancy.13 As in the more recent patients of the current series,
the positron emission tomography imaging is positive with
tumoral fixation.24
In 1984, Spencer25 proposed to use the term ‘‘plasma cell
histiocytoma complex’’ IPT and pulmonary histiocytofi-
broma as different stages in the progression of this disease.
He presented 27 pulmonary lesions, of which 2 progressed
into a sarcomatous variant. A new histologic classification
of pulmonary IPTs was presented by Gal and colleagues in
1994.2 They classified IPT as part of a continuum of pulmo-
nary fibrohistiocytic lesions that ranged from a typical in-
flammatory lesion without any evidence of malignancy to
a malignant histiocytofibroma. The spectrum included le-
sions such as benign fibrohistiocytoma, fibrohistiocytic
type, malignant fibrous histiocytoma, and pulmonary IPT.
Furthermore, they defined a subvariant of pulmonary IPT
Patients at risk
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FIGURE 3. Overall survival of the 25 patients after resection of pseudo-in-
flammatory tumor calculated with the Kaplan–Meier method.gery c February 2009
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leagues4 have divided pulmonary IPTs into 2 groups:
noninvasive and invasive IPT. They suggested an immuno-
histochemical study to distinguish a pulmonary IPT from
a spindle-cell carcinoma or anaplastic lymphoma.
IPT in pediatric patients has a high risk of locoregional ex-
tension. This invasive form is most often described in young
boys aged approximately 10 years.4 The mediastinal inva-
sion can reach the contralateral lung and result in severe me-
diastinal sclerosis, as we discovered in patient number 10.
IPTs of the lung have a high potential for local invasion.
Thus, vascular invasion,24 left ventricle invasion,26 and ver-
tebral invasion have been reported.25 Such infiltrating and
invading forms represent approximately 20% of thoracic
IPTs in children.4 In 6 of our cases, the local invasiveness
of the pulmonary IPT required a complex debulking opera-
tion: Two tumors invaded the carina, 2 tumors invaded the
thoracic inlet, 1 tumor invaded the right pulmonary artery,
and 1 tumor involved the mediastinum. Metastases are de-
scribed for abdominal IPT.10 Patient number 24 in our series
presented with 2 lesions: a right calcified lung tumor and
a cerebral metastasis. The histologic examination was the
same for both lesions. Metachronous cerebral metastasis
has also been described by Melloni and colleagues27 1
year after surgery; however, we could not find synchronous
cerebral metastasis for IPT of the lung in the literature. For
patient number 15, we found 2 tumor deposits on histologic
examination: One part was IPT, and 1 part was low-grade
sarcoma. This young boy had an invasive form, and the re-
currence of the sarcomatous portion was fatal.
Chromosomal abnormalities, such as translocations
(t [1;2) [q21;p23]) and deletions (del [4] [q27]), have been
described in up to 72% of cells, previously examined in
a 30-year-old woman with amiddle-lobe IPT.28 In contradis-
tinction to those who regard these lesions as benign, Snyder
and colleagues28 described them as potentially sarcomatous
lesions more than a simple inflammatory reaction. Biselli
and colleagues12 studied the ploidy of 9 pediatric IPTs. In
their study, 3 patients presented with a thoracic component.
Two of their patients had an invasive form, and 1 patient had
a metastatic lesion (these patients presented with a mesen-
teric lesion, colic lesion, and pulmonary lesion [a brain me-
tastasis subsequently developed in this patient]). In these 3
cases, there were some chromosomal abnormalities. For
the patient with metastasis, the primitive lesion and metasta-
sis had the same abnormalities but they were more pro-
nounced in the metastasis.
The treatment of choice for IPT of the lung is sur-
gery.4,7,21,22,27 For small peripheral tumors, it is now recom-
mended to perform a wedge resection and lobectomy when
the lesion is central. In other cases, when there is an invasion
of the chest wall, cervico-thoracic junction,main bronchus or
the carina, and diaphragm, an aggressive approachwith an en
bloc resection is necessary to ensure long-term survival.The Journal of Thoracic and CSteroid therapy has been used successfully by Bando and
colleagues29 for 2 patients as a primary mode of treatment.
However, in their report, the follow-up was short and no in-
formation on late recurrence was provided. This treatment
has also been used for IPTwith a contraindication for surgical
resection either because of invasive presentation deemed
unresectable or functionally inoperable patients.30-34 The re-
sults of corticosteroid treatment are widely variable, ranging
from inefficacy to complete regression.6,22,29-31
Six patients have been treatedwith chemotherapy;4,21,32,33
only 1 of them, treated with corticosteroids associated with 3
cycles of chemotherapy combining doxorubicin, cyclophos-
phamide, vinblastine, and bleomycin, had a complete regres-
sion of the tumor with a follow-up at 5 years.21 In 2 major
recurrences, Cerfolio and colleagues4 described a failure of
chemotherapy (agents not mentioned). Imperato and col-
leagues33 believe that in rare cases in which the lesion is lo-
cally aggressive and surgically unresectable or resectable
only with major morbidity, radiation therapy can be an effec-
tive alternative. Currently, the recommended treatment is
4000 to 4500 rads given in 180 to 200 rad fractions, with
the fields being carefully tailored to tumor volume to mini-
mize the dose to the surrounding normal tissue.33-35 Because
the results of chemotherapy and radiation therapy are also
widely variable, primary surgical treatment for most patients
is still recommended, especially in young patients who can
tolerate extended surgery. In case of contraindication to sur-
gical resection, we recommend steroid or chemotherapy
rather than radiation therapy to avoid local side effects.
CONCLUSIONS
IPT of the lung is rare but should be considered in the dif-
ferential diagnosis of a calcified solitary tumor in a young
patient. Despite the evidence that most of these tumors
show a benign clinical course, it is clear that these tumors
can have mediastinal invasion, local recurrences, metasta-
ses, and sarcomatous degeneration. These invasive presenta-
tions suggest that in reality they are malignant neoplasms.
We can also define 2 classes of tumor: peripheral tumors eas-
ily treated with wedge resection or lobectomy and central tu-
mors necessitating a resection that can be extended to the
tracheobronchial tree or adjacent organs. These tumors
should be removed or they can progress to malignant forms,
such as mesenchymal low-grade tumors. Once a complete
resection is performed for pulmonary IPTs, there is rarely
evidence of recurrence despite long-term follow-up. A com-
plete resection should always be attempted because it was
associated with a 10-year survival of 89% in our series.
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